Boston Scientific is looking ahead to the next-generation Acurate neo2 valve after results of SCOPE I showed worse rates of kidney injury and severe aortic regurgitation in patients treated with the self-expanding Acurate neo valve than in patients treated with Edwards’ Sapien 3 valve.
The 2019 Transcatheter Cardiovascular Therapeutics (TCT) conference was held in San Francisco from 24 September to 29 September • Source: shutterstock.com
Although the SCOPE I results are disappointing for the company, Boston Scientific remains committed to the Acurate neo platform as well as its Lotus Edge TAVR system, which was approved by the US Food and Drug Administration in April
